Gracell Biotechnologies, Inc. launches an IPO.

IPO of Gracell Biotechnologies, Inc. (GRCL) will take place of January 7, 2021. Gracell Biotechnologies is a global clinical stage biopharmaceutical company dedicated to the discovery and development of revolutionary cell-based cancer treatments. The company aims to change the traditional approaches to CAR-T cell therapy with its proprietary technology platforms - Fas TCAR and TruCAR. With FasTCAR the company can deliver younger, less depleted T-cels  for enhanced autocellular therapy, and with TruUCAR the company can obtain T-cells from healthy donors to create drugs to treat allogeneic CAR-T cells. All clinical development programs to date have been conducted in China.
Listed underwriters of the IPO are Citigroup, Jefferies, Piper Sandler and Wells Fargo.